HUNTSVILLE, Ala., Sept. 20, 2022 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has entered into an agreement with Olink Holding AB (publ) (Olink) and is installing the largest commercial platform of the Olink® technology in the Americas outside of Olink itself to become a leading global certified service provider for the Olink Proximity Extension Assay (PEA) technology, a unique anti-body based proteomic technology. Olink's PEA and Normalized Protein eXpression (NPX) Signature software, combined with Discovery's other leading multi-omic biomarker capabilities, provides the market with a global "one-stop shop" to support the discovery and validation of plasma proteomics at scale and with high specificity across all major biological pathways and sample matrices.
Read more at prnewswire.comDISCOVERY LIFE SCIENCES INSTALLS THE LARGEST OLINK PLATFORM IN THE AMERICAS TO SUPPORT PROTEOMICS RESEARCH & BIOMARKER DEVELOPMENT AT SCALE
PR Newswire -
Tue Sep 20, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Tesla%20car%20with%20symbol%20by%20Michael%20Fortsch%20via%20Unsplash.jpg)
/Unitedhealth%20Group%20Inc%20HQ%20photo-by%20jetcityimage%20via%20iStock.jpg)
/AI%20(artificial%20intelligence)/AI%20technology%20-%20by%20Wanan%20Yossingkum%20via%20iStock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20office%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)